Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib plus aromatase inhibitor for chemotherapy-insensitive high-risk luminal breast cancer
ChiCTR2400085698Phase 2Recruiting
- Sponsor
- Department of Breast Surgery, The First Hospital of China Medical University
- Start
- Jun 2024
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dalpiciclib and goserelin in breast cancer, sponsored by Department of Breast Surgery, The First Hospital of China Medical University. Primary endpoint: Preoperative endocrine prognostic index (PEPI) score. Started Jun 2024; status: recruiting.
02
Drugs
dalpiciclibgoserelin
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2400085698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085698.